CYP3A4 Gene Polymorphisms Influence Testosterone 6ß-hydroxylation

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 2, 2002, Pages 150-156

  Murayama, Norie ^a   Nakamura, Takahiro ^a   Saeki, Mayumi ^a   Soyama, Akiko ^a   Saito, Yoshiro ^a   Sai, Kimie ^a   Ishida, Seiichi ^a   Itoda, Masaya ^a   Ozawa, Shogo ^a   Sawada, Jun Ichi ^a   Nakajima, Osamu ^b   Ohno, Yasuo ^c  

^a Project Team for Pharmacogenetics   (Japan)

^b Division of Biochemistry and Immunochemistry   (Japan)

^c Division of Pharmacology   (Japan)

Author keywords

amino acid substitution; CYP3A4; metabolism; single nucleotide polymorphism (SNP); testosterone 6 hydroxylation

Indexed keywords

EID: 9144262579     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.150     Document Type: Article

References (33)

1. Guengerich, F. P.: Structure, Mechanism and Biochemistry. In Ortiz de Montellano, P. R. (ed.): Cytochrome P450: Plenum Press, New York, 1995, pp. 473-535.
2. Waxman, D. J., Attisano, C., Guengerich, F. P., and Lapenson, D. P.: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 b-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys., 263: 424-436 (1988).
3. Shimada, T. and Guengerich, F. P.: Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. USA, 86: 462-465 (1989).
4. Watkins, P. B.: Non-invasive tests of CYP3A enzymes. Pharmacogenetics, 4: 171-184 (1994).
5. Bertz, R. J. and Granneman, G. R.: Use of in vitro and in vivo data to estimate the likelihood of metabolic Pharmacokinetic interactions. Clin. Pharmacokinet., 32: 210-258 (1997).
6. Evans, W. E. and Relling, M. V.: Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science, 286: 487-491 (1999).
7. Walker, A. H., Jaffe, J. M., Gunasegaram, S., Cum-mings, S. A., Huang, C. S., Chern, H. D., Olopade, O. I., Weber, B. L. and Rebbeck, T. R.: Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat., 12: 289 (1998).
8. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V. P., Zheng, W., Raunio, H., Crespi, C. L. and Gonzalez, F. J.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clinical Pharmacol. Ther., 67: 48-56 (2000).
9. Peltonen, L., Jalanko, A., and Varilo, T.: Molecular genetics of the Finnish disease heritage. Hum. Mol. Genet., 8: 1913-1923 (1999).
10. Hsieh, K. P., Lin, Y. Y., Cheng, C. L., Lai, M. L., Lin, M. S., Siest, J. P. and Huang, J. D. : Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos., 29: 268-273 (2001).
11. Ged, C., Rouillon, J. M., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P. and Maurel, P.: The increase in urinary excretion of 6beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol., 28: 373-387 (1989).
12. Nakamura, T., Saito, Y., Murayama, N., Saeki, M., Soyama, A., Sai, K., Ozawa, S. and Sawada, J.: Apparent low frequency of sequence variability within the proximal promoter region of the cytochrome P450 (CYP) 3A5 gene in established cell lines from Japanese individuals. Biol. Pharm. Bull., 24: 954-957 (2001)
13. Gonzalez, F. J., Schmid, B. J., Umeno, M., Mcbride, O. W., Hardwick, J. P., Meyer, U. A., Gelboin, H. V. and Idle, J. R.: Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA, 7: 79-86 (1988).
14. Murayama, N., Sai, K., Nakajima, Y., Kaniwa, N., Ozawa, S., Ohno, Y. and Sawada, J. : Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jap. J. Cancer Res., 92: 524-528 (2001).
15. Murayama, N., Shimada, M., Yamazoe, Y., Sogawa, K., Nakayama, K, Fujii-Kuriyama, Y. and Kato, R.: Distinct effects of phenobarbital and its N-methylated derivative on liver cytochrome P450 induction. Arch. Biochem. Biophys., 328: 184-192 (1996).
16. Towbin, H., Staehelin, T. and Gordon, J.: Elec-trophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA., 76: 4350-4354 (1979).
17. Pampori, N. A., Pampori, M. K. and Shapiro, B. H.: Dilution of the chemiluminescence reagents reduces the background noise on western blots. Biotechniques, 18: 588-590 (1995).
18. Maniatis, T., Fritsch, E. F., and Sambrook, J. Molecular Cloning: A Laboratory Manual, second edition, New York, Cold Spring Harbor Laboratory Press, 1989, pp. 7.37-7.57.
19. Domanski, T. L., Liu, J., Harlow, G. R. and Halpert, J. R.: Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and a-naphthoflavone stimulation. Arch. Biochem. Biohys., 350: 223-232 (1998).
20. Poulos, T. L., Finzel, B. C. and Howard, A. J.: Highresolution crystal structure of cytochrome P450cam. J. Mol. Biol., 195: 687-700 (1987).
21. Ravichandran, K. G., Boddupalli, S. S., Hasermann, C. A., Peterson, J. A., Deisenhofer, J.: Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science, 261: 731-736 (1993).
22. Szklarz, G. D., Halpert, J. R.: Molecular modeling of cytochrome P450 3A4. J. Comput. Aided Mol. Des., 11: 265-272 (1997).
23. Poulos, T. L., Finzel, B. C., Gunsalus, I. C., Wagner, G. C. and Kraut, J.: The 2.6-crystal structure of Pseudomonas putida cytochrome P-450. J. Biol. Chem., 260: 16122-16130 (1985).
24. Schlichting, I., Berendzen, J., Chu, K., Stock, A. M., Maves, S. A., Benson, D. E., Sweet, R. M., Ringe, D., Petsko, G. A., and Sligar, S. G.: The catalytic pathway of cytochrome P450cam at atomic resolution. Science, 287: 1615-1622 (2000).
25. Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F. and McRee, D. E.: Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell., 5: 121-131 (2000).
26. Li, H., and Poulos, T. L.: The structure of the cytochrome P450BM-3 heme domain complexed with the fatty acid substrate, palmitoleic acid. Nat. Struct. Biol., 4: 140-146 (1997).
27. Gotoh, O.: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem., 267: 83-90 (1992).
28. He, Y. A., He, Y. Q., Szklarz, G. D. and Halpert, J. R.: Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. Biochemistry, 36: 8831-8839 (1997).
29. Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U. M., Brockmoller, J., Klenk, H. P., Meyer, U. A., Khan, K. K., He, Y. A., Halpert, J. R., Wojnowski, L.: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11: 447-458 (2001).
30. Cosme, J. and Johnson, E. F.: Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J. Biol. Chem., 275: 2545-2553 (2000).
31. Luo, Z., He, Y. A., and Halpert, J. R.: Role of residues 363 and 206 in conversion of cytochrome P450 2B1 from a steroid 16-hydroxylase to a 15 alpha-hydroxylase. Arch. Biochem. Biophys., 309: 52-57 (1994).
32. Johnson, E. F. and Waterman, M. R.: Structural alignments of P450s and extrapolations to the unknown. In Graham-Lorence, S. E. and Peterson, J. A. (ed.): Methods in Enzymology: Academic Press, 1996, pp. 315-327.
33. Stevens, J. C., Domanski, T. L., Harlow, G. R., White, R. B., Orton, E. and Halpert, J. R.: Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. J. Pharmacol. Exp. Ther., 290: 594-602 (1999).